CPRX Stock Summary and Trading Ideas (Catalyst Pharmaceuticals | NASDAQ:CPRX)

Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.

Catalyst Pharmaceuticals trades on the NASDAQ stock market under the symbol CPRX.

As of April 24, 2024, CPRX stock price climbed to $15.13 with 163,625 million shares trading.

CPRX has a beta of 1.27, meaning it tends to be more sensitive to market movements. CPRX has a correlation of 0.10 to the broad based SPY ETF.

CPRX has a market cap of $1.80 billion. This is considered a Small Cap stock.

In the last 3 years, CPRX stock traded as high as $22.11 and as low as $4.43.

The top ETF exchange traded funds that CPRX belongs to (by Net Assets): IJR, XBI, VTI, IWM, FBT.

CPRX has underperformed the market in the last year with a price return of -8.2% while the SPY ETF gained +24.5%. CPRX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning +1.3% and -4.2%, respectively, while the SPY returned +4.8% and -2.5%, respectively.

CPRX support price is $14.32 and resistance is $15.14 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CPRX stock will trade within this expected range on the day.